Boston Scientific Invests $1.5 Billion in MiRus for Revolutionary Nickel-Free TAVR Technology
核心洞察
Boston Scientific invested $1.5 billion for a 34% equity stake in MiRus LLC (搜索), securing exclusive option rights to acquire the company's innovative SIEGEL balloon-expandable TAVR system.
The SIEGEL valve represents the first nickel-free, balloon-expandable TAVR device built with proprietary rhenium alloy (搜索), offering superior radial strength and precise delivery through a 50% smaller sheath.
MiRus has initiated the STAR pivotal trial evaluating the SIEGEL valve in up to 1,025 patients with severe aortic stenosis (搜索) across all surgical risk categories.
Boston Scientific Corporation announced a strategic $1.5 billion investment in MiRus LLC (搜索), acquiring approximately 34% equity stake in the privately-held company developing innovative cardiovascular and orthopedic biomaterials. The investment includes exclusive option rights to acquire MiRus's breakthrough SIEGEL™ Balloon Expandable Transcatheter Aortic Valve (搜索) Replacement (TAVR) system, marking a significant advancement in structural heart intervention technology.
Revolutionary Rhenium Alloy Technology
The SIEGEL TAVR valve (搜索) represents the first nickel-free, balloon-expandable transcatheter aortic valve (搜索) designed to restore function and normal blood flow in severely narrowed aortic valves. Built on proprietary rhenium alloy (搜索) technology, the device features a nitric oxide-coated rhenium frame with radial strength greater than cobalt or titanium, according to ASTM standards specification.
"The occurrence and recognition of aortic stenosis (搜索) is growing rapidly and our investment in MiRus continues our pursuit to bring a differentiated TAVR system into our portfolio that we anticipate may improve outcomes for patients living with this life-threatening disease," said Lance Bates, executive vice president and president, Interventional Cardiology and Vascular Therapies at Boston Scientific.
Enhanced Delivery and Design Features
The SIEGEL valve incorporates several innovative design elements that distinguish it from current commercially available TAVR systems. The device features leaflets made of dry porcine tissue and an open cell frame design intended to eliminate foreshortening and enable precise placement in the heart. Uniquely, the valve comes pre-mounted directly onto the balloon, with all three sizes (23 mm, 26 mm, and 29 mm) deliverable through an 8 French expandable sheath.
This delivery system represents approximately 50% smaller profile compared to current commercially available TAVR delivery sheaths, based on Edwards eSheath+ Introducer Set specifications, potentially minimizing vascular injuries during the procedure.
Clinical Development Progress
MiRus recently initiated the STAR pivotal trial, a comprehensive study evaluating the safety and effectiveness of all three SIEGEL valve sizes in up to 1,025 patients with severe, symptomatic aortic stenosis (搜索). The trial includes patients considered to be at low, intermediate, or high risk for surgical complications, representing a broad patient population that could benefit from this technology.
The company previously presented findings from an early feasibility study assessing the safety and performance of the device, which according to MiRus founder and CEO Jay Yadav, M.D., has "received enthusiastic feedback from physician investigators for its less invasive delivery, nickel-free construct, precise placement resulting from a lack of foreshortening and excellent hemodynamics."
Strategic Acquisition Framework
The investment structure provides Boston Scientific with a clear pathway to full ownership of the TAVR technology. The company may exercise its option to acquire the MiRus TAVR business through additional aggregate cash payments totaling $3 billion, contingent upon MiRus achieving certain clinical and regulatory milestones. This acquisition would result in 100% ownership of the TAVR business, subject to customary closing conditions.
If Boston Scientific exercises the option, MiRus will retain rights to receive additional payments based on net sales of the SIEGEL TAVR valve (搜索) over a specified period. The agreement also grants Boston Scientific an exclusive option to acquire mitral and tricuspid replacement valve assets from MiRus for additional payment, potentially expanding the structural heart portfolio.
Market Impact and Future Outlook
The investment is expected to be immaterial to Boston Scientific's adjusted earnings per share for 2026. However, the strategic value extends beyond immediate financial impact, as Bates noted that the "distinctive design and impressive early clinical results of the SIEGEL valve may set it apart from currently available technology, potentially providing physicians an advanced option to treat a wide array of patients."
Dr. Yadav emphasized the collaborative potential, stating that "this collaborative relationship with Boston Scientific alongside the exceptional capabilities of our Atlanta-based team can further accelerate our progress towards broad accessibility for patients and physicians for what we believe will be a transformational treatment."
The SIEGEL TAVR system remains an investigational device not yet approved for commercial distribution in any country, with regulatory approval dependent on successful completion of ongoing clinical trials and regulatory review processes.